Janux Therapeutics, Inc.
No SEC Form 4 filings for $JANX in the last 30 days.
See all $JANX insider activity →Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.
Analysts upgraded four companies: Baird raised Darden (DRI) to Outperform with a $250 target, Wolfe upgraded Janux (JANX) to Outperform with a $23 target, UBS upgraded Celestica (CLS) to Buy with a $430 target, and Wolfe upgraded PulteGroup (PHM) to Outperform with a $129 target. All companies closed at or near their respective targets on Friday.
Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic
Over the past 7 days, AlphAI's AI scored 1 news story mentioning JANX (Janux Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent JANX coverage spans financial news, technology and earnings.
First‑in‑human dosing may trigger modest short‑term price movement and sets a timeline for upcoming safety data releases.
Positive analyst view may boost stock.
The 8-K provides fresh operational and financial datapoints for a clinical-stage biotech, mainly affecting near-term risk perception and runway expectations.
Routine shareholder-meeting outcomes; likely limited incremental impact beyond confirming governance items were approved.
Insider selling by a corporate/business development officer is a modest negative signal, but it is not a fundamental catalyst by itself.
AlphAI scores every news story that mentions JANX with an AI model for sentiment and relevance, and aggregates insider trades from Janux Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.
2 min readAnalysts upgraded four companies: Baird raised Darden (DRI) to Outperform with a $250 target, Wolfe upgraded Janux (JANX) to Outperform with a $23 target, UBS upgraded Celestica (CLS) to Buy with a $430 target, and Wolfe upgraded PulteGroup (PHM) to Outperform with a $129 target. All companies closed at or near their respective targets on Friday.
2 min readJanux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic
4 min readJanux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001817713 0001817713 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min readDoyle Janeen Noel (Chief Corp. & Bus. Dev. Ofcr) sold 4,059 shares of Janux Therapeutics, Inc. (JANX) at $14.03 on 2026-06-02.
1 min readThis article discusses the potential upside for Janux Therapeutics (JANX) as perceived by Wall Street analysts, who estimate a significant increase of 180.44%. It suggests that the stock could see substantial growth based on current analyst projections.
2 min readJanux Therapeutics reported a net loss of $24.4 million for Q1 2026, consistent with the prior year, but maintained a robust cash position of $956.4 million. The company received a $35 million milestone payment from Bristol Myers Squibb and continues to advance its clinical pipeline, including JANX007, JANX014, and JANX011, while discontinuing JANX008 to reallocate resources.
3 min readSeveral insiders at Janux Therapeutics (NASDAQ:JANX) have sold shares over the past year, which could be a warning sign for investors. Although insider selling can have various explanations, significant sales from multiple insiders warrant further investigation. While the insiders still hold a fair chunk of the company, the sales and two existing warning signs suggest caution for potential investors.
4 min readGuggenheim has reiterated its Buy rating on Janux Therapeutics (JANX.US) and maintained a target price of $68. This indicates the firm's continued confidence in the company's financial outlook and stock performance.
2 min readPoint72 entities, including Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen, have reported a 5.0% beneficial ownership stake in Janux Therapeutics (JANX). This disclosure was made via a Schedule 13G filing, indicating they collectively hold 3,069,759 shares with shared voting and dispositive power as of April 28, 2026. The filing explicitly states no sole voting or dispositive power and highlights a Joint Filing Agreement among the reporting persons.
2 min read
